Pharmaceutical Technology, Aug 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pharmaceutical Technology, Aug 1, 2012
Articles
CROs and CMOs Have Cause to Celebrate
By Jim Miller
Annual survey shows strong growth for service providers and promises to continue into 2013.
Quality by Design: A Contract Organization's Perspective
By Anil Kane
The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.
A Manufacturing Capacity-Sharing Model: Merck & Co. and MedImmune LLC
By Patricia Van Arnum
The manufacturing capacity-sharing model in biologics and Merck & Co. and MedImmune ushers in a new paradigm of "co-opetition".
Market Strengths and Weaknesses in Biosimilars
By Patricia Van Arnum
An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.
Strategies in Outsourcing: Insourcing Emerges as an Alternative Model
By Patricia Van Arnum
AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.
Strategies in Outsourcing Facilities Management
By Rakesh Kishan , Andrew Cieslak
The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.
Size Associations in the CRO Outsourcing Relationship
By Janice Hutt
The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here